1-3 of 3
Markus Boehm
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma

Lori S. Hart, JulieAnn Rader, Pichai Raman, Vandana Batra, Mike R. Russell, Matthew Tsang, Maria Gagliardi, Lucy Chen, Daniel Martinez, Yimei Li, Andrew Wood, Sunkyu Kim, Sudha Parasuraman, Scott Delach, Kristina A. Cole, Shiva Krupa, Markus Boehm, Malte Peters, Giordano Caponigro, John M. Maris
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (7): 1785–1796.
https://doi.org/10.1158/1078-0432.CCR-16-1131
Published: 02 April 2017
View article titled, Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma
Open the PDF for Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma in another window
Includes: Supplementary data
Journal Articles

Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

Clemens Krepler, Min Xiao, Katrin Sproesser, Patricia A. Brafford, Batool Shannan, Marilda Beqiri, Qin Liu, Wei Xu, Bradley Garman, Katherine L. Nathanson, Xiaowei Xu, Giorgos C. Karakousis, Gordon B. Mills, Yiling Lu, Tamer A. Ahmed, Poulikos I. Poulikakos, Giordano Caponigro, Markus Boehm, Malte Peters, Lynn M. Schuchter, Ashani T. Weeraratna, Meenhard Herlyn
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (7): 1592–1602.
https://doi.org/10.1158/1078-0432.CCR-15-1762
Published: 31 March 2016
View article titled, Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies
Open the PDF for Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies in another window
Includes: Supplementary data
Journal Articles

Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo

Wilko Weichert, Annika Röske, Silvia Niesporek, Aurelia Noske, Ann-Christin Buckendahl, Manfred Dietel, Volker Gekeler, Markus Boehm, Thomas Beckers, Carsten Denkert
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (6): 1669–1677.
https://doi.org/10.1158/1078-0432.CCR-07-0990
Published: 17 March 2008
View article titled, Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases <em>In vitro</em> and <em>In vivo</em>
Open the PDF for Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases <em>In vitro</em> and <em>In vivo</em> in another window
Includes: Supplementary data